RELENTLESS INVENTION
MENU > C O N T E N T S
3
4
5
REGENERON AT A GL ANCE
SHAREHOLDER LE T TER
MARK E TED PRODUC TS
8
CLINICA L-STAGE PIPELINE
13
16
18
24
25
26
E ARLY-STAGE PIPELINE / R + D
GROW TH
CITIZENSHIP
FORWARD-LOOK ING STATEMENTS
CORPOR ATE INFORMATION
REFERENCES
< MENU > REGENERON AT A GLANCE
4
FDA-approved
medicines
~3.5MILLION doses of EYLEA®
sold globally in 2015
12
antibodies in clinical trials
across multiple therapeutic areas
5 YRS
Ranked #1 or #2 employer in the global
biopharmaceutical industry in Science
Top Employers Survey 5 years in a row
68
peer-reviewed
publications
in 2015
2,118 volunteer
hours at
66 organizations through
Regeneron in the
Community program
4TH
Most Innovative
Company, according
to Forbes
Regeneron
employees
worldwide
consented individuals
sequenced by the
Regeneron Genetics Center
annual reduction
in greenhouse gas
emissions per employee
2 0 15 A NNUA L REP OR T
3
< MENU > DEAR SHAREHOLDERS,
2015 was a busy and rewarding year for Regeneron as we made major strides in advancing our mission of
bringing important new medicines to people with serious diseases, over and over again.
We delivered EYLEA® (aflibercept) Injection, our therapy for serious
vision-threatening diseases, to more and more patients, and we launched
PRALUENT® (alirocumab) Injection, a first-in-class therapy for uncontrolled
LDL cholesterol in certain patients.
In the next few years, we anticipate additional approvals for a number of new
therapies. In 2016, we look forward to potentially launching sarilumab for
rheumatoid arthritis, pending U.S. Food and Drug Administration (FDA) review
of our application. We also expect a potential U.S. regulatory submission for
dupilumab in atopic dermatitis, a serious form of eczema, for which we have
been granted a Breakthrough Therapy designation by the FDA.
Our pipeline of a dozen clinical-stage antibodies continues to progress, with
important programs in eye disease, cancer, infectious disease, pain,
cardiovascular disease and inflammation. We also continue to invest in
technology and innovation that will position us to bring needed new
medicines to patients for many years into the future. Likewise, we have made
important infrastructure investments to ensure our long-term success,
including adding two new buildings at our headquarters in Tarrytown, New
York, and expanding our Industrial Operations facilities in Rensselaer, New
York, and Raheen, Ireland.
We have always run Regeneron by the principle of “doing well by doing
good.” In addition to our work to invent new and needed medicines, we focus
on improving our world and operating with the highest standards of integrity.
This year, for the first time, our Annual Report integrates reporting on our
citizenship priorities and aspirations, in addition to our financial and business
performance.
We invite you to read about our 2015 accomplishments, financial
performance and citizenship efforts below and in our 2015 Annual Report on
Form 10-K, available on the Investor Relations portion of our website.
Unfortunately, there was also some sadness in 2015. Our longtime friend,
mentor, co-founder and Board member, Dr. Alfred G. Gilman, passed away in
December. Dr. Gilman was a Nobel Laureate who made lasting contributions
to science and medicine. On a personal level, we all benefited greatly from
Al’s counsel and wry wit over the years, and we will miss him greatly.
We look forward to updating you on our progress as we continue building
Regeneron into a leading global biopharmaceutical company.
Sincerely,
Leonard Schleifer, MD, PhD
Roy Vagelos, MD
George Yancopoulos, MD, PhD
2 0 15 A NNUA L REP OR T
4
< MENU > M A R K E T E D
P R O D U CTS
M A K E G R E AT M E D I C I N E .
T H E N D O I T A G A I N A N D A G A I N .
< MENU > EYLEA® (AFLIBERCEPT) INJECTION AND RETINAL DISEASE PROGRAMS
Market-leading VEGF-Trap approved in more than 100 countries for the treatment
of many blindness-causing retinal conditions, including wet age-related
macular degeneration and diabetic macular edema (DME).
EYLEA net sales in the U.S. increased 54% to $2.676 billion for the full year of 2015, from $1.736 billion for the
full year 2014. Outside of the U.S., where our collaborator Bayer HealthCare commercializes EYLEA, net
sales were $1.413 billion in 2015, compared to $1.039 billion in 2014. Regeneron recognized $467 million
from its share of net profit outside the U.S. in 2015, compared to $301 million in 2014.
EYLEA U.S. SALES:
54% INCREASE
$2.676 bn
This growth was driven in part by the publication in early 2015 of first-year results from an
independent National Institutes of Health (NIH)-sponsored comparative effectiveness study
in DME. In the study, at one year, EYLEA demonstrated a significantly greater
improvement in mean change in best-corrected visual acuity (BCVA) from baseline
compared to ranibizumab and bevacizumab, two other VEGF inhibitors used in
retinal disease. The rates of most ocular and systemic adverse events were
similar across the three study groups.
In 2016, we initiated a Phase 3 study of EYLEA in diabetic retinopathy
in patients without DME, a common degenerative eye disease that
impacts people with diabetes. We continue to explore EYLEA in
combination with other mechanisms, and have two ongoing
clinical programs in this area, aflibercept+PDGFR-beta
and aflibercept+ANG2, in collaboration with Bayer
HealthCare.
EYLEA EX-U.S. SALES:
36% INCREASE
$1.736 bn
$1.413 bn
$1.409 bn
$1.039 bn
$427.1 mm
2013
2014
2015
2013
2014
2015
2 0 15 A NNUA L REP OR T
6
< MENU > PRALUENT® (ALIROCUMAB) INJECTION
Only monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin
type 9) available in two doses, allowing for tailored therapy based on a patient’s
LDL-C lowering needs.
In July 2015, PRALUENT was approved by the FDA as adjunct to diet and maximally tolerated statin therapy for the treatment
of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require
additional lowering of LDL-C (often referred to as “bad cholesterol”). The effect of PRALUENT on cardiovascular
morbidity and mortality has not been determined.
Together with our collaborator Sanofi, the U.S. launch is underway. We have focused on physician education
about this new class, as well as achieving patient access and reimbursement coverage from health plans.
PRALUENT was also approved in the E.U., and launches are underway across the region.
The ongoing ODYSSEY OUTCOMES clinical trial program, which is evaluating the potential of
PRALUENT to prevent heart attacks, stroke and cardiac death, reached full enrollment in 2015,
with more than 18,000 patients at more than 2,000 study centers. Interim results are
possible in late 2016, and we expect full results in 2017.
ODYSSEY OUTCOMES
2 0 15 A NNUA L REP OR T
7
< MENU > C L I N I C A L- STA G E
P I P E L I N E
N E V E R STO P
A S K I N G W H Y.
< MENU > PIPELINE (as of April 2016)
Regeneron has a dozen fully human monoclonal antibodies in clinical development,
all of which were developed using our proprietary VelocImmune ® technology.
P H A S E 1
P H A S E 2
REGN1979
CD20/CD3 Antibody
Cancer
REGN1908-1909
Allergic disease
* in collaboration with Sanofi
^ in collaboration with Bayer HealthCare
†
in collaboration with Mitsubishi Tanabe
DUPILUMAB*
IL-4R Antibody
Atopic dermatitis in children, nasal
polyps, eosinophilic esophagitis
SARILUMAB*
IL-6R Antibody
Non-infectious uveitis
TREVOGRUMAB
GDF8 Antibody
Skeletal muscle disorders
REGN2176-3^
Rinucumab (PDGFR-beta
Antibody) + Aflibercept
Wet age-related macular
degeneration
EVINACUMAB
Angptl3 Antibody
Lipid disorders
REGN910-3^
Nesvacumab (Ang2
Antibody) + Aflibercept
Ophthalmology
REGN2810*
PD-1 Antibody
Cancer
FASINUMAB†
NGF Antibody
Chronic lower back pain
P H A S E 3
ALIROCUMAB*
PCSK9 Antibody
Cardiovascular outcomes
AFLIBERCEPT^
VEGF-Trap
Diabetic retinopathy without DME
SARILUMAB*
IL-6R Antibody
Rheumatoid arthritis
DUPILUMAB*
IL-4R Antibody
Atopic dermatitis in adults, asthma
REGN2222
RSV Antibody
Respiratory syncytial virus
FASINUMAB†
NGF Antibody
Pain due to osteoarthritis
2 0 15 A NNUA L REP OR T
9
< MENU > SARILUMAB
An anti-IL-6 monoclonal antibody under U.S. regulatory
review for the treatment of rheumatoid arthritis (RA).
In 2015, we reported positive data from three Phase 3 trials of sarilumab in
patients with rheumatoid arthritis. Together with our collaborator, Sanofi,
we submitted the U.S. Biologics License Application in November 2015
and were assigned a Prescription Drug User Fee Act (PDUFA) date
of October 30, 2016.
In March 2016, the Phase 3 SARIL-RA-MONARCH
monotherapy study met its primary endpoint by
demonstrating that sarilumab was superior to
adalimumab (Humira®) in improving signs and
symptoms of active RA at Week 24. The
incidence of adverse events, serious
adverse events, infections and
serious infections was generally
similar between groups.
U NME T NEED IN R HEU M ATO ID
A R T HR I T IS R EM A INS
RA IMPACTS MORE THAN
1.3 MILLION
AMERICANS 1
— While significant strides have been made in the treatment of RA, there are
continued unmet needs
— A central driver of the destructive effects of RA in the joints is persistently
elevated levels of IL-6, a signaling protein in the body.2-5 At normal levels, IL-6 is
responsible for contributing to the healing process after injury or infection.3,6-7
However, at persistently raised levels, IL-6 triggers inflammation that can destroy
bone and cartilage5,8-12
— IL-6 may also contribute to the multiple systemic effects of RA, including fatigue,
anemia and bone density loss2
2 0 15 A NNUA L REP OR T
10
< MENU > DUPILUMAB
A first-in-class investigational monoclonal antibody blocking IL-4
and IL-13, two key cytokines believed to be drivers in allergic
inflammation.
Dupilumab is being studied for the treatment of certain allergic conditions, including atopic
dermatitis (AD), uncontrolled asthma, nasal polyps and eosinophilic esophagitis.
Dupilumab was granted a Breakthrough Therapy designation by the FDA for the
treatment of adults with moderate-to-severe atopic dermatitis who are not
adequately controlled with topical prescription therapy and/or for whom
these treatments are not appropriate. We expect to submit an
application for FDA approval later this year.
In 2016, we reported positive topline results from two
large Phase 3 studies in atopic dermatitis and continue
to enroll patients in a second pivotal study in
asthma. In the atopic dermatitis studies, the
overall rate of adverse events was
comparable between the dupilumab
groups and the placebo groups.
ATOP I C DER M AT I T IS :
U NME T NEED IN A DE VA S TAT ING
A ND M ISU NDERS TOOD D ISE A SE
APPROXIMATELY
1.6 MILLION U.S. ADULTS
ARE ESTIMATED TO HAVE UNCONTROLLED
MODERATE-TO-SEVERE ATOPIC DERMATITIS 13
— Currently, only topical therapies have been
approved by the FDA
— Systemic immuno-suppressants are used
off-label, but can have significant side effects
2 0 15 A NNUA L REP OR T
1 1
< MENU > REGN2222
FASINUMAB
A fully human monoclonal antibody being
investigated for the prevention of serious lower
respiratory tract infections associated with
Respiratory Syncytial Virus (RSV).
In 2015, we initiated the Phase 3 NURSERY-Pre-term trial that will evaluate the
efficacy, safety, pharmacokinetics and immunogenicity of REGN2222 in infants
under the age of six months.
An antibody targeting nerve growth factor being
evaluated for the potential to offer a novel,
non-opioid approach to addressing chronic pain.
Two clinical trials of fasinumab for pain due to osteoarthritis and chronic back
pain were initiated in 2016. In 2015, we entered into a collaboration with
Mitsubishi Tanabe Pharma Corporation to develop and commercialize fasinumab
in Japan, Korea and nine other Asian countries (excluding China).
U NME T NEED I N A
V U L NER A B L E P OP U L AT I ON
U NME T NEED IN
C HRON I C PA IN
APPROXIMATELY
50 MILLION
U.S. ADULTS
SUFFER FROM SIGNIFICANT
CHRONIC OR SEVERE PAIN 15
2 0 15 A NNUA L REP OR T
12
REGN22221 IN 5 INFANTSUNDER 6 MONTHS WILL REQUIRE MEDICAL ATTENTION FOR RSV14< MENU >
E A R LY- STA G E
P I P E L I N E / R + D
O U R G R E AT E ST D I S C O V E R I E S
H AV E Y E T TO B E D E F I N E D .
< MENU > IMMUNO-ONCOLOGY
RAPID RESPONSE +
INFECTIOUS DISEASE
Building on our existing Sanofi antibody
collaboration, we launched a new $2.2B global
immuno-oncology collaboration with Sanofi.
This new undertaking will provide important new resources to advance our
portfolio in this rapidly developing field, which seeks to harness the body’s
immune system to fight cancer.
We continued to explore multiple approaches in immuno-oncology, including
bispecific antibodies, checkpoint inhibitors and antibody drug conjugates. We
have two antibodies, a CD20/CD3 bispecific antibody and a PD-1 inhibitor, in
clinical studies with data expected in 2016. A number of additional
immuno-oncology antibodies are expected to enter the clinic this year and next.
Regeneron’s Rapid Response capabilities leverage
our core VelociSuite ® technologies to significantly
compress the time required for discovery and
preclinical validation of potential treatments for
emerging infectious diseases.
In 2015, we identified and validated a novel therapeutic cocktail of three
antibodies targeting the Ebola virus, and reached an agreement with the
Biomedical Advanced Research and Development Authority (BARDA) of the U.S.
Department of Health and Human Services to develop, test and manufacture
this potential treatment. A Phase 1 study in healthy volunteers is planned for the
first half of 2016. We similarly identified and validated an antibody against
MERS (Middle East Respiratory Virus) and are working to advance this
program, as well as pursuing antibody therapies for other devastating viral
diseases such as Zika and Dengue.
2 0 15 A NNUA L REP OR T
1 4
< MENU > REGENERON GENETICS CENTER
In its second full year, the Regeneron
Genetics Center (RGC) continued to grow
rapidly in terms of scope, scale and speed.
The RGC was created to elucidate, on a large scale, genetic factors that
cause or influence a range of human diseases. The team has sequenced
over 100,000 exomes to date, and is now delivering new target
opportunities and validating existing targets in our preclinical and clinical
programs. We continued to bring world-class collaborators from industry,
academia and leading health-systems on board, and published the RGC’s
first peer-reviewed publication in the New England Journal of Medicine.
2 0 15 A NNUA L REP OR T
15
< MENU > G R OWT H
B E A N E N G I N E
O F I N V E N T I O N .
< MENU > GROWTH
In 2015, we grew in many aspects of our business.
We continued construction of our world-class, 400,000-square-foot manufacturing facility in Limerick, Ireland,
which will significantly expand our biologic supply capabilities for commercial products. We opened new
buildings in our Rensselaer Industrial Operations headquarters and our Tarrytown R&D laboratories and
corporate headquarters. And we welcomed our 4,000th Regeneron employee, all while remaining focused on
sustaining the innovative culture that makes us unique.
REVENUE
$4.104 bn
FULL-TIME EMPLOYEES
4,300
(650 with PhD and/or
MD or PharmD)
R&D INVESTMENT*
$1.621 bn
$2.820 bn
$2.105 bn
46 %
increase
2,925
2,340
47%
increase
$1.271 bn
$860 mm
2013
2014
2015
2013
2014
2015
2013
2014
2015
28 %
increase
* Generally Accepted
Accounting Principles
R&D Expenses
2 0 15 A NNUA L REP OR T
1 7
< MENU > C I T I Z E N S H I P
D O I N G W E L L ,
BY D O I N G G O O D .
< MENU > COMMITTED TO A BETTER FUTURE
In addition to our work to invent new and needed
medicines, we are focused on improving our world
and operating with the highest standards of
integrity. We are proud not only of what we do, but
how we do it.
These four pillars help us articulate how we view
our responsibility and commitment to society:
FOSTERING
the future
of scientific
innovation
NURTURING
our
high-engagement,
high-integrity
culture
CULTIVATING
sustainable
communities
SUPPORTING
patient
communities
2 0 15 A NNUA L REP OR T
19
< MENU > FOSTERING THE FUTURE OF SCIENTIFIC INNOVATION
We believe our STEM (Science, Technology, Engineering and Math) education is a top priority;
we are focused on ensuring a strong pipeline of STEM talent for many years to come.
Spanning from elementary school to postdoctoral fellowships, our STEM programs spark interest in
science and enhance knowledge, scientific research and careers in biotechnology.
AT TR ACT, SUPPORT AND REWARD
the best and brightest minds in science research
Our immersive internship program offers college and graduate students a uniquely collaborative work
environment to gain hands-on, real-world experience. We are also a founding supporter and title sponsor
of the Westchester Science and Engineering Fair (affiliated with the International Science and Engineering
Fair, or ISEF) high school science research competition, and award the Regeneron Prize to graduate and
postdoctoral students every year.
INCRE ASE THE EFFECTIVENESS
of teachers in STEM
Created in partnership with the STEM Leadership Center, our teaching fellowship gives New York state-certified
middle and high school science teachers the tools they need to deliver higher-quality instruction.
BRIDGE STEM SKILLS GAPS AND CAREER AWARENESS
among students historically underrepresented in the sciences
Our Sci2Med Academy initiative with Yonkers Partners in Education is an after-school program for high school
juniors that broadens knowledge of science and awareness of careers in biotechnology. Students have the
opportunity to learn about biotechnology and drug discovery, hear from Regeneron researchers and tour the labs.
Science Education hours:
Number of REGN Interns:
19,000
196
2 0 15 A NNUA L REP OR T 2 0
< MENU >
CULTIVATING SUSTAINABLE COMMUNITIES
We proudly support the communities where we work and live, and that includes a
company-wide commitment to environmental sustainability.
Community Service
Regeneron in the Community (RIC), our company
volunteer program, unites our people through days of
service, company-sponsored activities and employee-led
projects. RIC inspires action, fosters collaboration and
motivates our people to self-organize around service
projects that reflect their individual passions.
2,118
volunteer
hours at
66 organizations
through RIC
600additional organizations
supported through the
Matching Gifts Program
93%
of employees feel good about the ways
we contribute to the community
— Great Places to Work Employee Survey
In 2013, we set five-year targets in four
key areas to help inform our choices and
actions, all with the aim of reducing our
environmental footprint as we grow.
Environmental Sustainability
We want to grow our business while reducing
our environmental impact. We proactively seek
environmentally responsible ways to better operate
our business now and in the future, and we focus
on environmental stewardship throughout our
value chain.
CARBON *
Reduced our carbon footprint
per employee by 14%,
moving toward our expanded
2018 goal of 30%
ELECTRICITY*
Reduced our consumption
per employee by 5%, moving
toward our 2018 goal of 10%
WASTE
44% of our waste avoids the landfill,
moving toward our 2018 goal of 90%
HAZARDOUS CHEMICAL WASTE
51% reduction per lab employee,
just short of our 2018 goal of 60%
*Carbon and Electricity are reported based on the Carbon Disclosure Project reporting year; 2013 noted above corresponds to June 2013 – May 2014 reporting year.
2 0 15 A NNUA L REP OR T
2 1
< MENU >
SUPPORTING PATIENT COMMUNITIES
Our employees are focused on putting science, technology and
innovation to work to make a difference in patients’ lives.
This effort starts in the labs, moves into the clinic and continues with our commitment to ensuring patients
can access the therapies they need.
Comprehensive patient programs, like MyPraluent™ and EYLEA4USM, provide support for patients
throughout their treatment journey by offering insurance eligibility support, financial assistance and free
medicine to eligible patients. Additional services include access to educational information and clinical
support for physicians, nurses and pharmacists.
Regeneron does not influence or control the operations of independent co-pay assistance foundations and
cannot guarantee assistance will be provided.
We also aim to support community needs through unique programs
and active engagement with the advocacy organizations that represent
the patients we serve.
ITNAmerica/Rides in Sight
Regeneron is a national Eye-Care Services Sponsor for ITNAmerica/Rides in Sight.
Advocacy Partnerships
Our company was built on the fundamental goal of helping patients, and we regularly
ITNAmerica is the first, national non-profit transportation network committed to
engage with advocacy organizations to help empower patients. For example, we partnered
providing safe, low-cost, community-based transportation options for seniors and
those with vision loss to help them maintain their independence.
with the Arthritis Foundation to create patient advocacy summits and patient ambassador
programs, all with the goal of catalyzing national and local advocacy efforts.
2 0 15 A NNUA L REP OR T 2 2
< MENU >
NURTURING OUR HIGH-ENGAGEMENT, HIGH-INTEGRITY CULTURE
We empower our people to thrive personally and professionally, work together to create
positive change, and promote an ethical culture of diversity and inclusion.
4TH
Most Innovative Company,
according to Forbes
2ND
CONSECUTIVE YEAR
100 Best Companies
to Work For, Fortune
5 YRS
Ranked #1 or #2 employer in the
global biopharmaceutical industry
in Science Top Employers Survey
5 years in a row
95%
of employees say
“I’m proud to tell others I work here”
- Great Places to Work Employee Survey
We work hard to nurture our highly ethical culture through:
Opportunities for Growth
We encourage and assist our employees in their quests to continue learning
throughout their careers.
Culture of Collaboration
We thrive on diverse ideas and individuals who aren’t afraid to challenge
convention, and we believe our next great discovery could spring from any
level of the organization.
Integrity at Work
We pride ourselves on doing the right thing and have rigorous
policies in place to ensure that our colleagues, vendors and
business partners are acting in accordance with all applicable
laws, rules and regulations.
2 0 15 A NNUA L REP OR T 2 3
< MENU >
FORWARD-LOOKING STATEMENTS
This Annual Report includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron
Pharmaceuticals, Inc. (“we,” “us,” “our,” “Regeneron,” or the “Company”), and actual events or results may differ materially from these forward-looking statements.
Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words and similar expressions are intended to identify such
forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties
include, among others, the nature, timing, and possible success and therapeutic applications of our products, product candidates, and research and clinical programs
now underway or planned, including without limitation EYLEA® (aflibercept) Injection, PRALUENT® (alirocumab) Injection, sarilumab, dupilumab, fasinumab, REGN 2222,
and the immuno-oncology program; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious
complications or side effects in connection with the use of our product candidates in clinical trials; the likelihood and timing of possible regulatory approval and
commercial launch of our late-stage product candidates and new indications for marketed products, including without limitation EYLEA®, PRALUENT®, sarilumab,
dupilumab, fasinumab, and REGN 2222; ongoing regulatory obligations and oversight impacting our marketed products (such as EYLEA® and PRALUENT®), research
and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may
delay or restrict our ability to continue to develop or commercialize our products and product candidates; competing drugs and product candidates that may be superior
to our products and product candidates; uncertainty of market acceptance and commercial success of our products and product candidates; our ability to manufacture
and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and
Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; our ability to meet any of its sales or other financial projections or guidance
and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi
and Bayer HealthCare LLC, to be canceled or terminated without any further product success; and risks associated with third-party intellectual property and pending
or future litigation relating thereto. A more complete description of these and other material risks can be found in our filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (filed with the Securities and Exchange Commission on February
11, 2016), including in the section thereof captioned “Item 1A. Risk Factors.” Any forward-looking statements are made based on management’s current beliefs and
judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. We do not undertake any obligation to update publicly any
forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
2 0 15 A NNUA L REP OR T 24
< MENU > CORPORATE INFORMATION
Common Stock and Related Matters
Our Common Stock is traded on The NASDAQ Global Select Market under the symbol “REGN.” Our Class A Stock is not publicly quoted or traded.
The following table sets forth, for the periods indicated, the range of high and low sales prices for the Common Stock as reported by The NASDAQ Global Select Market.
2014
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
HIGH
$352.49
$320.00
$369.31
$437.64
LOW
$262.97
$269.50
$285.06
$320.06
2015
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
HIGH
$495.50
$544.00
$605.93
$592.59
LOW
$393.00
$433.47
$435.52
$488.10
As of April 14, 2016, there were 211 shareholders of record of our Common Stock and 23 shareholders of record of our Class A Stock.
The closing sales price for the Common Stock on that date was $406.83.
We have never paid cash dividends and do not anticipate paying any in the foreseeable future.
SEC Form 10-K
A copy of our 2015 Annual Report on Form 10-K filed with the Securities and Exchange
Commission (which accompanies and forms part of this 2015 Annual Report to Shareholders) is
available without charge from the Regeneron Investor Relations Department.
2016 Annual Shareholder Meeting
The 2016 Annual Shareholder Meeting will be held on
Friday, June 10, 2016, at 10:30 a.m. at the Westchester
Marriott Hotel, 670 White Plains Road, Tarrytown, New
York 10591.
Shareholders’ Inquiries
Inquiries relating to stock transfer or lost certificates and notices of changes of address should be directed to our Transfer Agent, American Stock Transfer & Trust
Co., 6201 15th Avenue, Brooklyn, New York 11219, (800) 937-5449, www.amstock.com/main. General information regarding the Company, recent press releases, and
SEC filings are available on our website at www.regeneron.com, or can be obtained by contacting our Investor Relations Department at (914) 847-7741.
Corporate Office
777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
(914) 847-7400
Transfer Agent and Registrar
American Stock Transfer & Trust Co.
6201 15th Avenue
Brooklyn, New York 11219
Independent Registered Public Accounting Firm
PricewaterhouseCoopers LLP
REGENERON®, Science to Medicine®, and the following are registered trademarks of Regeneron Pharmaceuticals, Inc.: ARCALYST®, EYLEA®, VelociGene®, and
VelocImmune®. PRALUENT® is a registered trademark of Sanofi.
2 0 15 A NNUA L REP OR T 2 5
< MENU >
REFERENCES
1. American College of Rheumatology. “Rheumatoid Arthritis.”
Available at: http://www.rheumatology.org/I-Am-A/Patient-
Caregiver/Diseases-Conditions/Rheumatoid-Arthritis.
Last accessed: September 2015.
2. Choy E. Rheumatology (Oxford). 2012;51(suppl 5):v3-v11.
3. Dayer JM, et al. Rheumatology (Oxford). 2010;49(1):15-24.
4. Ito A, et al. Arthritis Rheum. 1992;35(10):1197-1201.
5. Wong PK, et al. Arthritis Rheum. 2006;54(1):158-168.
6. McInnes IB. Cytokines. In: Firestein GS, Budd RC, Gabriel SE,
McInnes IB, O’Dell JR, eds. Kelley’s Textbook of Rheumatology.
Vol 1. 9th ed. Philadelphia, PA: Elsevier/Saunders; 2013:369-381.
7. Saxena A, Cronstein BN. In: Firestein GS, Budd RC, Gabriel SE,
McInnes IB, O’Dell JR, eds. Kelley’s Textbook of Rheumatology.
Vol 1. 9th ed. Philadelphia, PA: Elsevier/Saunders; 2013:818-829.
8. Maggio M, et al. J Gerontol A Biol Sci Med Sci. 2006;61(6):575-584.
9. Garnero P, et al. Arthritis Rheum. 2010;62(1):33-43.
10. Ishimi Y, et al. J Immunol. 1990;145(10):3297-3303.
11. Choy EH, et al. Nat Rev Rheumatol. 2013;9(3):154-163.
12. Bartok B, et al. Immunol Rev. 2010;233(1):233-255.
13. Adelphi Final Report 2014/2015, data on file.
14. Centers for Disease Control and Prevention. “Infection and Incidence.”
Available at: http://www.cdc.gov/rsv/about/infection.html.
Last accessed: March 2016.
15. American Pain Society, “Estimates of Pain Prevalence and Severity in
Adults: United States, 2012.” Available at http://www.jpain.org/article/
S1526-5900(15)00679-3/pdf. Last accessed: March 2016.
2 0 15 A NNUA L REP OR T 2 6
< MENU